Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

NCT05800756 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: pyrotinib combined with trastuzumab, dalpiciclib and letrozole

Sponsor

Yantai Yuhuangding Hospital

Collaborators

[object Object]